Tag: Zepbound
FDA approves GLP-1 for OSA
December 23, 2024HME News Staff
WASHINGTON – The U.S. Food and Drug Administration announced Dec. 20 that it has approved Zepbound (tirzepatide) for the treatment of moderate to severe sleep apnea in adults with obesity to be used in combination with a reduced-calorie diet and increased physical activity.
“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical...
Food & Drug Administration (FDA), Sleep Apnea, weight loss drugs, Zepbound
Sponsored Stories
From Intake to Billing — SOS Handles It All for HME/DME Providers
By Strategic Office SupportHow Advanced Diabetes Supply is Driving Value-Based Health Outcomes
By Advanced Diabetes SupplySOS Achieves Remarkable 400% Growth in 2023, Bolsters Team with Director Appointment
By Strategic Office Support